Data results expected to be available in 1H 2023
GAITHERSBURG, Md. and SUZHOU, China , Nov. 8, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the Company has dosed the first patient in a Phase I clinical study of STP705, a siRNA (small interfering RNA) drug candidate, for the study of fat reduction in adults undergoing abdominoplasty. In this clinical trial, Sirnaomics has the opportunity to study a leading siRNA therapeutic candidate for medical aesthetics treatment.
The dose-ranging, randomized, double-blind, vehicle-controlled study has 10 patients currently enrolled to evaluate the safety and tolerability of STP705, which is administered via subcutaneous injection. The primary endpoints are to assess injection comfort, characterize local and systemic safety, and evaluate histological changes of subcutaneous doses of STP705. The safety and tolerability will be compared among three different concentrations of STP705 (120ug/mL, 240ug/mL, 320ug/mL) to select dosages for future studies.
"Currently, the majority of non-invasive procedures approved in the U.S. to abolish fat cells require devices that have mild therapeutic effects and multiple treatment sessions. Our team expects that this dose finding study of STP705 will give key insights into the drugs' effect on fat reduction and subcutaneous tissue remodeling and provide key insights into how this therapeutic can be applied in a safe and effective manner to Medical Aesthetics." said Dr. Michael Molyneaux , M.D., Executive Director and Chief Medical Officer of Sirnaomics. "This Phase I study will help us mapping out future studies of STP705 for areas of the body that could be treated with non-invasive methods of fat sculpting."
Non-invasive fat reduction is a procedure that decreases or eliminates stubborn fat pockets in specific areas of the body by using methods like cryolipolysis, radio frequency, and laser lipolysis. The global market size of non-invasive fat reduction was valued at US$1.1 billion in 2021, with the U.S. having the largest market share, and is anticipated to have an annual growth rate of 16.1% from 2022 to 2030[1]. The Asia Pacific region is expected to outgrow the rest of the world at a pace of 17% over the same period due to factors such as rising obese population, increasing healthcare expenditure, increasing adoption of advanced technology and rising awareness by social media platforms.
"A non-invasive fat-reduction option will potentially offer millions of people with submental fat, which is resistant to diet and exercise and influenced by aging and genetics, a unique way to address an all-too-common condition," said Dr. Patrick Lu , Founder, Chairman of the Board, Executive Director, President and CEO of Sirnaomics. "After receiving the green light on an IND in the U.S., we look forward to better understanding how efficacious STP705 can be as a medical aesthetics treatment."
Additional information about this clinical trial is available at clinicaltrials.gov using the identifier: NCT05422378.
Sirnaomics' leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the U.S. Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA), including treatments of cholangiocarcinoma, non-melanoma skin cancer and hypertrophic scar. STP705 has also received Orphan Drug Designation for treatment of cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC). STP705 is currently in seven clinical trials for different indications: a Phase IIb for squamous cell carcinoma in situ (isSCC), a Phase II for basal cell carcinoma (BCC), a Phase I/II for keloid scarring, a Phase I/II for hypertrophic scar (HTS), a Phase I/II for facial isSCC, a Phase I for liver cancer (basket), and a Phase I for medical aesthetics treatment.
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States , and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.
Michael Molyneaux , M.D., MBA Executive Director and Chief Medical Officer, Sirnaomics Email: MichaelMolyneaux@sirnaomics.com
Investor Relations: Nigel Yip , MBA Chief Financial Officer, China , Sirnaomics Email: NigelYip@sirnaomics.com
US Media Contact: Mark Corbae Tel: +1 203 682 8288 Email: Mark.Corbae@westwicke.com
Asia Media Contact: Bunny Lee Tel: +852 3150 6707 Email: sirnaomics.hk@pordahavas.com
[1] Grand View Research (2022), Non-invasive Fat Reduction Market Size Report, 2022-2030
Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study. An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib ar
Only last week, the company was warned about its stock price; this week it's looking at putting a premium on the price of its second FDA-approved drug.
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
The FDA has a bevy of safety concerns surrounding Verve's gene-editing approach to high cholesterol, leading VERV stock to crash Monday.
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI). Let's consider why Editas Medicine and BioXcel Therapeutics are worth keeping an eye on right now, and whether the potential rewards of investing in these companies outweigh the risks. The company is down by 61% this year, a terrible performance it partly owes to market-wide troubles.
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.
Editas Medicine Inc (NASDAQ: EDIT) announced initial clinical data from the first two sickle cell disease (SCD) patients treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Additionally, neither patient has experienced any
In its response to a lawsuit brought by Covid-19 vaccine competitor Moderna Inc., Pfizer Inc. does not mince words: Pfizer did not copy Moderna's patented technology, it says, and Moderna is rewriting history by claiming otherwise.
Emergent BioSolutions Inc. (NYSE: EBS) has cleared an important hurdle in a bid to make its opioid overdose antidote available to the public without a doctor’s order. The Gaithersburg company said Tuesday that the Food and Drug Administration has accepted its supplemental new drug application for Narcan Nasal Spray, currently available with a prescription, as an emergency over-the-counter treatment for opioid overdose. The FDA expects to issue its decision of approval or denial March 29, 2023.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Shares of Gossamer Bio Inc. plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s sotatercept. "We expect the street to be disappointed in these topline results given both
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood,1 the peer-reviewed international medical journal of the American So
The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.
SimpleImages / GettyThe fight against COVID seems to have fallen into a ping-ponging rhythm at this point, where every step forward seems undercut by one backward. Vaccines are available, and hospitalization rates have fallen dramatically from previous peaks. But just a sliver of eligible Americans have received the most recent bivalent shot, and the specter of a new, somehow worse variant looms large in our collective psyche. Elsewhere, such as in China, we seem to be losing ground to the virus
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclin
(Bloomberg) -- Verve Therapeutics Inc. shares fell the most in five months, pulling down shares of rival drugmakers, after the biotechnology company said US regulators requested additional information before allowing a test of its gene therapy to begin. Most Read from Bloomberg‘Huge, Missing and Growing:’ $65 Trillion in Dollar Debt Sparks ConcernStocks Hit by Fed-Hike Jitters as US Yields Surge: Markets WrapRussia Blames Ukraine for Blasts at Bases That Damaged WarplanesElon Musk’s Impossible E
A for-profit California company saw windfall dividend — and patients scrambled for care, a CBS News investigation found.
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
A Texas woman is out on bond after authorities say she repeatedly stabbed her boyfriend on Thanksgiving after accusing him of “not helping her with the bills,” according to court records. Cassandra Gutierrez, 30, was released on bond Thursday after being charged with aggravated assault with a deadly weapon for the alleged stabbing, which left her boyfriend injured but alive, Law & Crime reports. Gutierrez and her 42-year-old boyfriend had been dating for about a year when investigators said they